{
    "nct_id": "NCT04150497",
    "official_title": "Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)",
    "inclusion_criteria": "* B-ALL blast cells expressing CD22\n* Diagnosed with R/R B-ALL\n* Prior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen\nHealthy volunteers allowed\nMust have minimum age of 15 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "-Prior cellular therapy or investigational cellular or gene therapy within 60 days prior to enrollment",
    "miscellaneous_criteria": ""
}